1. Home
  2. HSPO vs VTGN Comparison

HSPO vs VTGN Comparison

Compare HSPO & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSPO
  • VTGN
  • Stock Information
  • Founded
  • HSPO 2014
  • VTGN 1998
  • Country
  • HSPO United States
  • VTGN United States
  • Employees
  • HSPO N/A
  • VTGN N/A
  • Industry
  • HSPO Blank Checks
  • VTGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSPO Finance
  • VTGN Health Care
  • Exchange
  • HSPO Nasdaq
  • VTGN Nasdaq
  • Market Cap
  • HSPO 49.4M
  • VTGN 62.9M
  • IPO Year
  • HSPO 2022
  • VTGN N/A
  • Fundamental
  • Price
  • HSPO $11.79
  • VTGN $2.25
  • Analyst Decision
  • HSPO
  • VTGN
  • Analyst Count
  • HSPO 0
  • VTGN 0
  • Target Price
  • HSPO N/A
  • VTGN N/A
  • AVG Volume (30 Days)
  • HSPO 294.0
  • VTGN 92.2K
  • Earning Date
  • HSPO 01-01-0001
  • VTGN 06-10-2025
  • Dividend Yield
  • HSPO N/A
  • VTGN N/A
  • EPS Growth
  • HSPO N/A
  • VTGN N/A
  • EPS
  • HSPO 0.27
  • VTGN N/A
  • Revenue
  • HSPO N/A
  • VTGN $698,000.00
  • Revenue This Year
  • HSPO N/A
  • VTGN N/A
  • Revenue Next Year
  • HSPO N/A
  • VTGN N/A
  • P/E Ratio
  • HSPO $44.35
  • VTGN N/A
  • Revenue Growth
  • HSPO N/A
  • VTGN N/A
  • 52 Week Low
  • HSPO $10.87
  • VTGN $1.90
  • 52 Week High
  • HSPO $12.41
  • VTGN $4.75
  • Technical
  • Relative Strength Index (RSI)
  • HSPO 46.31
  • VTGN 47.44
  • Support Level
  • HSPO $11.78
  • VTGN $2.10
  • Resistance Level
  • HSPO $11.90
  • VTGN $2.45
  • Average True Range (ATR)
  • HSPO 0.02
  • VTGN 0.13
  • MACD
  • HSPO -0.02
  • VTGN 0.02
  • Stochastic Oscillator
  • HSPO 4.76
  • VTGN 55.56

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Share on Social Networks: